• Michael Place, MD (Major General, US Army – Retired) – Former Chief of Staff, Office of the Surgeon General, US Army Command, US Army
• Erica Pan, MD, MPH – Director and State Public Health Officer, California Department of Public Health
• Alex Hamberg, VMD, PhD – State Veterinarian, Pennsylvania Department of Agriculture
• Clint Osborn – Director, District of Columbia Homeland Security and Emergency Management Agency
• Lori Tremmel Freeman, MBA – Chief Executive Officer, National Association of County and City Health Officials
• Tina Tan, MD, FIDSA, FPIDS, FAAP – President, Infectious Disease Society of America
• Ali S. Khan, MD, MPH – Dean, College of Public Health, University of Nebraska Medical Center
• Richard J. Hatchett, MD – Chief Executive Officer, Coalition for Epidemic Preparedness Innovations
• Matthew Hepburn, MD – Executive Vice President, Research and Development, Panther Life Sciences
• Leonard J. Marcus, PhD – Co-Director, National Preparedness Leadership Initiative, Harvard University
• Taylor Sexton, MPH – Executive Director, Medical Countermeasures Coalition
• David Stiefel, MA – Director, Global Biological Policy and Programs, Nuclear Threat Initiative
• Joe Buccina, MA, MS– Policy and Research Director, National Security Commission on Emerging Biotechnology
• Patricia R. Bright, DVM – Former Senior Science Advisor, One Health/Global Health Security, US Geological Survey

Learn more here: https://biodefensecommission.org/events/biodefense-in-crisis-danger-and-opportunity/

This Commission meeting, Astrobiodefense: Biological Threats and the Next Frontier, was held on May 8, 2025. The focus of this meeting will be to provide the Bipartisan Commission on Biodefense with a better understanding of how to strengthen international astrobiodefense and planetary protection efforts through: (1) current government astrobiodefense efforts; (2) new scientific and technological advances for astrobiodefense; and (3) collaborative efforts and public-private partnerships to improve astrobiodefense.

See more information here: https://biodefensecommission.org/events/astrobiodefense-biological-threats-and-the-next-frontier/

The Commission's May 8, 2025 meeting began with Executive Director Dr. Asha M. George delivering the first annual State of National Biodefense address. The increasing biological threat and uncertainty surrounding federal biodefense programs and capabilities necessitates a clear-eyed examination of the threat and US efforts to address critical capability gaps. This address will lay out the current realities of national biodefense and the Commission’s vision for a future where the Nation can more effectively prevent, deter, prepare for, detect, respond to, attribute, recover from, and mitigate biological incidents.

Read her written testimony here: https://biodefensecommission.org/the-state-of-u-s-biodefense-written-remarks-by-dr-asha-m-george/

This Commission meeting, Under the Weather: The Nexus of Climate Change and Biodefense, was held on Thursday, December 5, 2024 at 58 East 68th St., New York, NY 10065. The focus of this meeting was to provide the Bipartisan Commission on Biodefense with a better understanding of: 1) the effects of climate change on human health and one health, 2) the future implications of migration and shifting disease patterns, and 3) policy considerations to reduce the inevitable impacts of climate change on biodefense.

Learn more here: https://biodefensecommission.org/events/fluency-true-expertise-and-effectiveness-in-the-battle-against-influenza-2/

The Commission meeting, FLUency: True Expertise and Effectiveness in the Battle Against Influenza, was held on Tuesday, October 8th, in Washington, DC. The focus of this meeting is to provide the Bipartisan Commission on Biodefense with a better understanding of: (1) national leadership to defend food and agriculture against influenza; (2) federal operational requirements for preparedness, coordination, and response; (3) biosurveillance, forecasting, and the need for diagnostic tests; and (4) front-line needs and partnerships in the fight against influenza.

Learn more here: https://biodefensecommission.org/events/fluency-true-expertise-and-effectiveness-in-the-battle-against-influenza-2/

In this meeting, the Bipartisan Commission on Biodefense will explore: (1) how the federal government currently addresses indoor air quality; (2) new scientific and technological advances for indoor air quality; and (3) how enhancing indoor air quality can help prevent the spread of pathogens.

Learn more here: https://biodefensecommission.org/events/masters-of-the-air-overcoming-airborne-pathogens-indoors/

We all lost a visionary leader and friend with the unexpected passing of Senator Joe Lieberman, who along with Governor Tom Ridge co-chaired the Bipartisan Commission on Biodefense for ten years.

His death came just as the Commission was preparing to release our 2024 National Blueprint for Biodefense: Immediate Action Needed to Defend Against Biological Threats. Senator Lieberman, who worked tirelessly to defend Americans against biological threats, was a driving force behind this report. So, it is only fitting that we host a special tribute to Senator Lieberman as we publicly release the new National Blueprint for Biodefense.

The Bipartisan Commission on Biodefense (formerly the Blue Ribbon Study Panel on Biodefense) was established in 2014 to provide a comprehensive assessment of the state of United States biodefense efforts and to issue recommendations that foster change. Subsequently, the Commission has briefed White House Administrations (including then Vice President Biden); testified before Congress; convened numerous meetings with experts; released 12 reports; produced the graphic novel Germ Warfare; and mobilized biodefense conversations and actions in the private and public sectors.

In its  2015 bipartisan report,  A National Blueprint for Biodefense: Leadership and Major Reform Needed to Optimize Efforts, the Commission described biological threats to the Nation and made 33 recommendations to optimize US efforts to prevent, deter, prepare for, detect, respond to, attribute, recover from, and mitigate intentionally introduced, accidentally released, and naturally occurring biological events. Many recommendations from this report have been taken up by the government, including the National Biodefense Strategy, a federal biodefense budget crosscut by the Office of Management and Budget, and the recent Biodefense Posture Review by the Department of Defense.

The world continues to experience rising threats from offensive biological weapons programs, lab accidents, and outbreaks affecting our national security. There have been burgeoning biotechnological advances in medical countermeasures (e.g., antibiotics, antivirals, vaccines, diagnostics) yet huge gaps in prevention, deterrence, preparedness, detection, response, attribution, recovery, and mitigation still remain. The federal government must address gaps in the US biodefense enterprise. Nine years after its seminal report, the Commission is releasing the 2024 National Blueprint on Biodefense with specific recommendations for government leaders in Congress and the Administration to strengthen the federal government’s biodefense posture.

Learn more here: A Tribute to Senator Lieberman with the Release of the 2024 National Blueprint for Biodefense - Bipartisan Commission on Biodefense (biodefensecommission.org)

This meeting was recorded on Tuesday, December 5, 2023. Find more information about this meeting here: Meeting the Moment: Biodefense Policy, Procurement, and Public Health - Bipartisan Commission on Biodefense (biodefensecommission.org)

As the Nation continues to endure the consequences of recent pandemics, and with continued interest in biological weapons by nation states and other enemies, the federal government has an opportunity to address vulnerabilities in the biodefense enterprise. At this meeting, titled Meeting the Moment: Biodefense Policy, Procurement, and Public Health, the Commission intends to further explore : (1) biodefense policies and activities at the Department of Defense; (2) federal stockpile evaluation and decision-making for smallpox medical countermeasures; (3) needed authorities of the Department of Health and Human Services, including the Centers for Disease Control and Prevention; and (4) biodefense leadership.